Mediastinal Lymphoproliferative Disorders.
Journal
Advances in anatomic pathology
ISSN: 1533-4031
Titre abrégé: Adv Anat Pathol
Pays: United States
ID NLM: 9435676
Informations de publication
Date de publication:
01 Sep 2021
01 Sep 2021
Historique:
pubmed:
3
6
2021
medline:
30
9
2021
entrez:
2
6
2021
Statut:
ppublish
Résumé
Lymphoproliferative disorders comprise 50% to 60% of all mediastinal malignancies in both children and adults. Primary mediastinal involvement is rare (∼5%), whereas secondary mediastinal involvement by systemic disease is more common (10% to 25%). Primary mediastinal disease is defined as involvement by a lymphoproliferative disorder of mediastinal lymph nodes, the thymus, and/or extranodal mediastinal organs without evidence of systemic disease at presentation. In this review, the clinical, radiologic, histopathologic, immunohistochemical, and genetic features of some of the most characteristic mediastinal lymphoproliferative disorders are presented. The entities discussed here include: classic Hodgkin lymphoma with emphasis on nodular sclerosis and mixed cellularity types, and non-Hodgkin lymphomas, including primary mediastinal (thymic) large B-cell lymphoma, mediastinal gray zone lymphoma, mediastinal diffuse large B-cell lymphoma, thymic marginal zone lymphoma, mediastinal plasmacytoma, T-lymphoblastic lymphoma, and anaplastic large cell lymphoma. Although not a malignant process, hyaline vascular Castleman disease is also discussed here as this disorder commonly involves the mediastinum. Despite multiple advances in hematopathology in recent decades, the day-to-day diagnosis of these lesions still requires a morphologic approach and a proper selection of immunohistochemical markers. For this reason, it is crucial for general pathologists to be familiar with these entities and their particular clinicoradiologic presentation.
Identifiants
pubmed: 34074861
doi: 10.1097/PAP.0000000000000305
pii: 00125480-202109000-00004
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
307-334Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The author has no funding or conflicts of interest to disclose.
Références
Temes R, Allen N, Chavez T, et al. Primary mediastinal malignancies in children: report of 22 patients and comparison to 197 adults. Oncologist. 2000;5:179–184.
Temes R, Chavez T, Mapel D, et al. Primary mediastinal malignancies: findings in 219 patients. West J Med. 1999;170:161–166.
Macchiarini P, Ostertag H. Uncommon primary mediastinal tumours. Lancet Oncol. 2004;5:107–118.
Strickler JG, Kurtin PJ. Mediastinal lymphoma. Semin Diagn Pathol. 1991;8:2–13.
Kahlor N, Moran C Kalhor N, Moran C. Lymphoproliferative disorders. Mediastinal Pathology. Cham, Switzerland: Springer; 2019:521–577.
Pina-Oviedo S, Moran CA. Primary mediastinal classical Hodgkin lymphoma. Adv Anat Pathol. 2016;23:285–309.
Pina-Oviedo S, Moran CA. Primary mediastinal nodal and extranodal non-Hodgkin lymphomas: current concepts, historical evolution, and useful diagnostic approach: part 1. Adv Anat Pathol. 2019;26:346–370.
Pina-Oviedo S, Moran CA. Primary mediastinal nodal and extranodal non-Hodgkin lymphomas: current concepts, historical evolution, and useful diagnostic approach: part II. Adv Anat Pathol. 2019;26:371–389.
Benjamin SP, McCormack LJ, Effler DB, et al. Primary lymphatic tumors of the mediastinum. Cancer. 1972;30:708–712.
Smetana HF, Cohen BM. Mortality in relation to histologic type in Hodgkin’s disease. Blood. 1956;11:211–224.
Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin’s disease. Cancer Res. 1966;26:1063–1083.
Brice P, de Kerviler E, Friedberg JW. Classical Hodgkin lymphoma. Lancet. 2021;22:S0140-6736(20)32207-8.
Tomiyama N, Honda O, Tsubamoto M, et al. Anterior mediastinal tumors: diagnostic accuracy of CT and MRI. Eur J Radiol. 2009;69:280–288.
Inaoka T, Takahashi K, Iwata K, et al. Evaluation of normal fatty replacement of the thymus with chemical-shift MR imaging for identification of the normal thymus. J Magn Reson Imaging. 2005;22:341–346.
Inaoka T, Takahashi K, Mineta M, et al. Thymic hyperplasia and thymus gland tumors: differentiation with chemical shift MR imaging. Radiology. 2007;243:869–876.
Takahashi K, Inaoka T, Murakami N, et al. Characterization of the normal and hyperplastic thymus on chemical-shift MR imaging. AJR Am J Roentgenol. 2003;180:1265–1269.
Hess JL, Bodis S, Pinkus G, et al. Histopathologic grading of nodular sclerosis Hodgkin’s disease. Lack of prognostic significance in 254 surgically staged patients. Cancer. 1994;74:708–714.
Ferry JA, Linggood RM, Convery KM, et al. Hodgkin disease, nodular sclerosis type. Implications of histologic subclassification. Cancer. 1993;71:457–463.
Masih AS, Weisenburger DD, Vose JM, et al. Histologic grade does not predict prognosis in optimally treated, advanced-stage nodular sclerosing Hodgkin’s disease. Cancer. 1992;69:228–232.
Kuppers R, Hansmann ML. The Hodgkin and Reed/Sternberg cell. Int J Biochem Cell Biol. 2005;37:511–517.
Chan WC. The Reed-Sternberg cell in classical Hodgkin’s disease. Hematol Oncol. 2001;19:1–17.
Hummel M, Marafioti T, Stein H. Clonality of Reed-Sternberg cells in Hodgkin’s disease. N Engl J Med. 1999;340:394–395.
Stein H, Hummel M. Cellular origin and clonality of classic Hodgkin’s lymphoma: immunophenotypic and molecular studies. Semin Hematol. 1999;36:233–241.
Re D, Müschen M, Ahmadi T, et al. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res. 2001;61:2080–2084.
Andorsky DJ, Yamada RE, Said J, et al. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17:4232–4244.
Paydas S, Bağir E, Seydaoglu G, et al. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. Ann Hematol. 2015;94:1545–1552.
Tanaka Y, Maeshima AM, Nomoto J, et al. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma. Eur J Haematol. 2018;100:511–517.
Xie W, Medeiros LJ, Li S, et al. PD-1/PD-L1 pathway and its blockade in patients with classic Hodgkin lymphoma and non-Hodgkin large-cell lymphomas. Curr Hematol Malig Rep. 2020;15:372–381.
Gomez-Gelvez JC, Smith LB. Reed-Sternberg-like cells in non-Hodgkin lymphomas. Arch Pathol Lab Med. 2015;139:1205–1210.
O’Malley DP, Dogan A, Fedoriw Y, et al. American Registry of Pathology Expert Opinions: immunohistochemical evaluation of classic Hodgkin lymphoma. Ann Diagn Pathol. 2019;39:105–110.
Etienne B, Guillaud PH, Loire R, et al. Aggressive primary mediastinal non-Hodgkin’s lymphomas: a study of 29 cases. Eur Respir J. 1999;13:1133–1138.
Gonin J, Kadiri H, Bensaci S, et al. Primary mediastinal anaplastic alk-1-positive large-cell lymphoma of T/NK-cell type expressing CD20. Virchows Arch. 2007;450:355–358.
Xing X, Feldman AL. Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous. Adv Anat Pathol. 2015;22:29–49.
Thomas RK, Re D, Wolf J, et al. Part I: Hodgkin’s lymphoma—molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol. 2004;5:11–18.
Schwering I, Bräuninger A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003;101:1505–1512.
Hinz M, Lemke P, Anagnostopoulos I, et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin’s disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med. 2002;196:605–617.
Hinz M, Löser P, Mathas S, et al. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood. 2001;97:2798–2807.
Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002;99:618–626.
Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25:2679–2684.
Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34:2690–2697.
Farrell K, Jarrett RF. The molecular pathogenesis of Hodgkin lymphoma. Histopathology. 2011;58:15–25.
Klapper W, Jaffe E, Gaulard P, et al. Travis W, Brambilla E, Burke A, Marx A, Nicholson A. Primary mediastinal large B-cell lymphoma. WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 4th ed. Lyon: IARC; 2015:267–269.
Lichtenstein AK, Levine A, Taylor CR, et al. Primary mediastinal lymphoma in adults. Am J Med. 1980;68:509–514.
Miller JB, Variakojis D, Bitran JD, et al. Diffuse histiocytic lymphoma with sclerosis: a clinicopathologic entity frequently causing superior venacaval obstruction. Cancer. 1981;47:748–756.
Cazals-Hatem D, Lepage E, Brice P, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d’Etude des Lymphomes de l’Adulte”) study. Am J Surg Pathol. 1996;20:877–888.
Dunleavy K. Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies. Hematology Am Soc Hematol Educ Program. 2017;2017:298–303.
Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851–862.
Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006;17:123–130.
Davis RE, Dorfman RF, Warnke RA. Primary large-cell lymphoma of the thymus: a diffuse B-cell neoplasm presenting as primary mediastinal lymphoma. Hum Pathol. 1990;21:1262–1268.
Lamarre L, Jacobson JO, Aisenberg AC, et al. Primary large cell lymphoma of the mediastinum. A histologic and immunophenotypic study of 29 cases. Am J Surg Pathol. 1989;13:730–739.
Menestrina F, Chilosi M, Bonetti F, et al. Mediastinal large-cell lymphoma of B-type, with sclerosis: histopathological and immunohistochemical study of eight cases. Histopathology. 1986;10:589–600.
Moller P, Lammler B, Eberlein-Gonska M, et al. Primary mediastinal clear cell lymphoma of B-cell type. Virchows Arch A Pathol Anat Histopathol. 1986;409:79–92.
Moller P, Moldenhauer G, Momburg F, et al. Mediastinal lymphoma of clear cell type is a tumor corresponding to terminal steps of B cell differentiation. Blood. 1987;69:1087–1095.
Nakagawa A, Nakamura S, Koshikawa T, et al. Clinicopathologic study of primary mediastinal non-lymphoblastic non-Hodgkin’s lymphomas among the Japanese. Acta Pathol Jpn. 1993;43:44–54.
Yousem SA, Weiss LM, Warnke RA. Primary mediastinal non-Hodgkin’s lymphomas: a morphologic and immunologic study of 19 cases. Am J Clin Pathol. 1985;83:676–680.
Tateishi U, Muller NL, Johkoh T, et al. Primary mediastinal lymphoma: characteristic features of the various histological subtypes on CT. J Comput Assist Tomogr. 2004;28:782–789.
Shimosato Y, Mukai K. Atlas of Tumor Pathology Tumors of the Mediastinum, 3rd ed. Washington: Armed Forces Institute of Pathology; 1995.
Pileri SA, Gaidano G, Zinzani PL, et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol. 2003;162:243–253.
de Leval L, Ferry JA, Falini B, et al. Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells? Am J Surg Pathol. 2001;25:1277–1282.
Hoeller S, Zihler D, Zlobec I, et al. BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin’s lymphoma from primary mediastinal large B-cell lymphoma. Histopathology. 2010;56:217–228.
Higgins JP, Warnke RA. CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol. 1999;112:241–247.
Calaminici M, Piper K, Lee AM, et al. CD23 expression in mediastinal large B-cell lymphomas. Histopathology. 2004;45:619–624.
Copie-Bergman C, Plonquet A, Alonso MA, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol. 2002;15:1172–1180.
Gentry M, Bodo J, Durkin L, et al. Performance of a commercially available MAL antibody in the diagnosis of primary mediastinal large B-cell lymphoma. Am J Surg Pathol. 2017;41:189–194.
Pelland K, Mathews S, Kamath A, et al. Dendritic cell markers and PD-L1 are expressed in mediastinal gray zone lymphoma. Appl Immunohistochem Mol Morphol. 2018;26:e101–e106.
Shi M, Roemer MG, Chapuy B, et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol. 2014;38:1715–1723.
Bledsoe JR, Redd RA, Hasserjian RP, et al. The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome. Am J Hematol. 2016;91:E436–E441.
Lees C, Keane C, Gandhi MK, et al. Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. Br J Haematol. 2019;185:25–41.
Guiter C, Dusanter-Fourt I, Copie-Bergman C, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood. 2004;104:543–549.
Menter T, Tzankov A. Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy. Virchows Arch. 2019;474:497–509.
Mottok A, Woolcock B, Chan FC, et al. Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression. Cell Rep. 2015;13:1418–1431.
Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123:2062–2065.
Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med. 2009;206:981–989.
Mansouri L, Noerenberg D, Young E, et al. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood. 2016;128:2666–2670.
Tsang P, Cesarman E, Chadburn A, et al. Molecular characterization of primary mediastinal B cell lymphoma. Am J Pathol. 1996;148:2017–2025.
Jaffe ES, Stein H, Swerdlow SH, et al. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Lyon: IARC; 2008:267–268.
Jaffe ES, Stein H, Swerdlow SH, et al. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, revised 4th ed. Lyon: IARC; 2017:342–344.
Schurch CM, Federmann B, Quintanilla-Martinez L, et al. Tumor heterogeneity in lymphomas: a different breed. Pathobiology. 2018;85:130–145.
Wilson WH, Pittaluga S, Nicolae A, et al. A prospective study of mediastinal gray-zone lymphoma. Blood. 2014;124:1563–1569.
Evens AM, Kanakry JA, Sehn LH, et al. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol. 2015;90:778–783.
Grant C, Dunleavy K, Eberle FC, et al. Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do? Curr Hematol Malig Rep. 2011;6:157–163.
Sarkozy C, Molina T, Ghesquieres H, et al. Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. Haematologica. 2017;102:150–159.
Sarkozy C, Copie-Bergman C, Damotte D, et al. Gray-zone lymphoma between cHL and large B-cell lymphoma: a histopathologic series from the LYSA. Am J Surg Pathol. 2019;43:341–351.
O’Malley DP, Fedoriw Y, Weiss LM. Distinguishing classical Hodgkin lymphoma, gray zone lymphoma, and large B-cell lymphoma: a proposed scoring system. Appl Immunohistochem Mol Morphol. 2016;24:535–540.
Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102:3871–3879.
Suster S, Moran CA. Pleomorphic large cell lymphomas of the mediastinum. Am J Surg Pathol. 1996;20:224–232.
Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
Klui PM, Harris NL, Stein H, et al. Swerdlow SH, Campo E, Harris NL, et al. High-grade B-cell lymphoma. WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues. Lyon: IARC; 2017:335–341.
Go H, Cho HJ, Paik JH, et al. Thymic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a clinicopathological and genetic analysis of six cases. Leuk Lymphoma. 2011;52:2276–2283.
Lorsbach RB, Pinkus GS, Shahsafaei A, et al. Primary marginal zone lymphoma of the thymus. Am J Clin Pathol. 2000;113:784–791.
Sakamoto T, Yamashita K, Mizumoto C, et al. MALT lymphoma of the thymus with Sjogren’s syndrome: biphasic changes in serological abnormalities over a 4-year period following thymectomy. Int J Hematol. 2009;89:709–713.
Shimizu K, Yoshida J, Kakegawa S, et al. Primary thymic mucosa-associated lymphoid tissue lymphoma: diagnostic tips. J Thorac Oncol. 2010;5:117–121.
Weissferdt A, Moran CA. Primary MALT-type lymphoma of the thymus: a clinicopathological and immunohistochemical study of six cases. Lung. 2011;189:461–466.
Isaacson PG, Chan JK, Tang C, et al. Low-grade B-cell lymphoma of mucosa-associated lymphoid tissue arising in the thymus. A thymic lymphoma mimicking myoepithelial sialadenitis. Am J Surg Pathol. 1990;14:342–351.
Takagi N, Nakamura S, Yamamoto K, et al. Malignant lymphoma of mucosa-associated lymphoid tissue arising in the thymus of a patient with Sjogren’s syndrome. A morphologic, phenotypic, and genotypic study. Cancer. 1992;69:1347–1355.
Weissferdt A, Moran CA. Thymic hyperplasia with lymphoepithelial sialadenitis (LESA)-like features: a clinicopathologic and immunohistochemical study of 4 cases. Am J Clin Pathol. 2012;138:816–822.
Giroux Leprieur E, Antoine M, Gounant V, et al. Association between thymic MALT lymphoma and Sjogren’s syndrome. Rev Pneumol Clin. 2009;65:108–112.
Kurabayashi A, Iguchi M, Matsumoto M, et al. Thymic mucosa-associated lymphoid tissue lymphoma with immunoglobulin-storing histiocytosis in Sjogren’s syndrome. Pathol Int. 2010;60:125–130.
Shimizu K, Ishii G, Nagai K, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in the thymus: report of four cases. Jpn J Clin Oncol. 2005;35:412–416.
Muramatsu T, Tanaka Y, Higure R, et al. Thymic and pulmonary mucosa-associated lymphoid tissue lymphomas. Ann Thorac Surg. 2013;95:e69–e70.
Nagasaka T, Lai R, Harada T, et al. Coexisting thymic and gastric lymphomas of mucosa-associated lymphoid tissues in a patient with Sjogren syndrome. Arch Pathol Lab Med. 2000;124:770–773.
Sunohara M, Hara K, Osamura K, et al. Mucosa associated lymphoid tissue (MALT) lymphoma of the thymus with trisomy 18. Intern Med. 2009;48:2025–2032.
Yamanaka S, Uekusa T, Tajiri M. Mucosa-associated lymphoid tissue lymphoma in the thymus with multiple amyloid nodules in the both lungs. Kyobu Geka. 2010;63:392–395.
Kuroki S, Nasu K, Murakami K, et al. Thymic MALT lymphoma: MR imaging findings and their correlation with histopathological findings on four cases. Clin Imaging. 2004;28:274–277.
Yi JG, Kim DH, Choi CS. Malignant lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) arising in the thymus: radiologic findings. AJR Am J Roentgenol. 1998;171:899–900.
Arai H, Tajiri M, Kaneko S, et al. Two surgical cases of thymic MALT lymphoma associated with multiple lung cysts: possible association with Sjogren’s syndrome. Gen Thorac Cardiovasc Surg. 2017;65:229–234.
Kang LY, Ho SP, Chou YP. Primary thymic mucosa-associated lymphoid tissue lymphoma with multiple thin walled lung cysts: case report and literature review. Chin J Cancer Res. 2013;25:354–357.
Moriyama E, Yokose T, Kodama T, et al. Low-grade B-cell lymphoma of mucosa-associated lymphoid tissue in the thymus of a patient with pulmonary amyloid nodules. Jpn J Clin Oncol. 2000;30:349–353.
Balakrishna JP, Jaffe ES. Crystal-storing histiocytosis associated with thymic extranodal marginal zone lymphoma. Blood. 2017;130:1683.
Yoshida M, Okabe M, Eimoto T, et al. Immunoglobulin VH genes in thymic MALT lymphoma are biased toward a restricted repertoire and are frequently unmutated. J Pathol. 2006;208:415–422.
Harigae H, Ichinohasama R, Miura I, et al. Primary marginal zone lymphoma of the thymus accompanied by chromosomal anomaly 46,X,dup(X)(p11p22). Cancer Genet Cytogenet. 2002;133:142–147.
Kominato S, Nakayama T, Sato F, et al. Characterization of chromosomal aberrations in thymic MALT lymphoma. Pathol Int. 2012;62:93–98.
Momoi A, Nagai K, Isahai N, et al. Thymic extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with 8q24 abnormality. Intern Med. 2016;55:799–803.
Takino H, Li C, Yamada S, et al. Thymic extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue: a gene methylation study. Leuk Lymphoma. 2013;54:1742–1746.
Inagaki H, Chan JK, Ng JW, et al. Primary thymic extranodal marginal-zone B-cell lymphoma of mucosa-associated lymphoid tissue type exhibits distinctive clinicopathological and molecular features. Am J Pathol. 2002;160:1435–1443.
Ortonne N, Copie-Bergman C, Remy P, et al. Mucosa-associated lymphoid tissue lymphoma of the thymus: a case report with no evidence of MALT1 rearrangement. Virchows Arch. 2005;446:189–193.
Ganesh M, Sankar NS, Jagannathan R. Extramedullary plasmacytoma presenting as upper back pain. J R Soc Promot Health. 2000;120:262–265.
Lee SY, Kim JH, Shin JS, et al. A case of extramedullary plasmacytoma arising from the posterior mediastinum. Korean J Intern Med. 2005;20:173–176.
Moran CA, Suster S, Fishback NF, et al. Extramedullary plasmacytomas presenting as mediastinal masses: clinicopathologic study of two cases preceding the onset of multiple myeloma. Mod Pathol. 1995;8:257–259.
Jacob JJ, John M, Thomas M, et al. Plasmacytoma mimicking mediastinal parathyroid tumour in a patient with primary hyperparathyroidism. Asian J Surg. 2007;30:147–150.
Miyazaki T, Kohno S, Sakamoto A, et al. A rare case of extramedullary plasmacytoma in the mediastinum. Intern Med. 1992;31:1363–1365.
Raci-Wetherbee E, Dincer HE. IgG myeloma presenting as a large mediastinal mass and pleural effusion. J Bronchology Interv Pulmonol. 2012;19:65–67.
Salem KZ, Nishihori T, Kharfan-Dabaja MA, et al. Primary plasmacytoma involving mediastinal lymph nodes: a diagnostic mimicry of primary mediastinal lymphoma. Hematol Oncol Stem Cell Ther. 2016;9:26–29.
Bassan R, Maino E, Cortelazzo S. Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment. Eur J Haematol. 2016;96:447–460.
Cortelazzo S, Ferreri A, Hoelzer D, et al. Lymphoblastic lymphoma. Crit Rev Oncol Hematol. 2017;113:304–317.
Maeshima AM, Taniguchi H, Suzuki T, et al. Distribution of malignant lymphomas in the anterior mediastinum: a single-institution study of 76 cases in Japan, 1997-2016. Int J Hematol. 2017;106:675–680.
Dong M, Zhang X, Yang Z, et al. Patients over 40 years old with precursor T-cell lymphoblastic lymphoma have different prognostic factors comparing to the youngers. Sci Rep. 2018;8:1088.
Jin X, Zhao HF, Yu Y, et al. Analysis of clinical characteristics and prognostic factors of primary mediastinal T-cell lymphoblastic lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21:377–382.
Watanabe T, Shimomura H, Mutoh T, et al. Positron emission tomography/computed tomography as a clinical diagnostic tool for anterior mediastinal tumors. Surg Today. 2019;49:143–149.
Abruzzo LV, Jaffe ES, Cotelingam JD, et al. T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy. Am J Surg Pathol. 1992;16:236–245.
Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol. 2010;41:461–476.
Vega F, Medeiros LJ, Bueso-Ramos CE, et al. Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. Am J Clin Pathol. 2015;144:377–392.
Vega F, Medeiros LJ, Davuluri R, et al. t(8;13)-positive bilineal lymphomas: report of 6 cases. Am J Surg Pathol. 2008;32:14–20.
Chisholm KM, Krishnan C, Heerema-McKenney A, et al. Immunohistochemical profile of MYC protein in pediatric small round blue cell tumors. Pediatr Dev Pathol. 2017;20:213–223.
Siegert E, Weissbach G, Fischer R, et al. Non-Hodgkin lymphoma (NHL) as a second neoplasm occurring after neuroblastoma treatment. Med Pediatr Oncol. 1998;30:18–21.
Boddu P, Thakral B, Alhuraiji A, et al. Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation. J Clin Pathol. 2019;72:251–257.
Adam P, Hakroush S, Hofmann I, et al. Thymoma with loss of keratin expression (and giant cells): a potential diagnostic pitfall. Virchows Arch. 2014;465:313–320.
Bhaker P, Das A, Rajwanshi A, et al. Precursor T-lymphoblastic lymphoma: speedy diagnosis in FNA and effusion cytology by morphology, immunochemistry, and flow cytometry. Cancer Cytopathol. 2015;123:557–565.
Gorczyca W, Tugulea S, Liu Z, et al. Flow cytometry in the diagnosis of mediastinal tumors with emphasis on differentiating thymocytes from precursor T-lymphoblastic lymphoma/leukemia. Leuk Lymphoma. 2004;45:529–538.
Ward N, Baqai J, Zehnpfennig A, et al. Bcl-2 maturation pattern in T-cells distinguishes thymic neoplasm/hyperplasia, T-lymphoblastic lymphoma, and reactive lymph nodes. Cytometry B Clin Cytom. 2018;94:444–450.
Sekimizu M, Sunami S, Nakazawa A, et al. Chromosome abnormalities in advanced stage T-cell lymphoblastic lymphoma of children and adolescents: a report from Japanese Paediatric Leukaemia/Lymphoma Study Group (JPLSG) and review of the literature. Br J Haematol. 2011;154:612–617.
Borowitz MJ, Chan JKC, Bene M-C, et al. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R. T-lymphoblastic leukemia/lymphoma. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissue, Revised 4th ed. Lyon: IARC; 2017:209–212.
Bongiovanni D, Saccomani V, Piovan E. Aberrant signaling pathways in T-cell acute lymphoblastic leukemia. Int J Mol Sci. 2017;18:E1904.
Sevilla DW, Choi JK, Gong JZ. Mediastinal adenopathy, lung infiltrates, and hemophagocytosis: unusual manifestation of pediatric anaplastic large cell lymphoma: report of two cases. Am J Clin Pathol. 2007;127:458–464.
Makiguchi N, Ohsaki Y, Fujiuchi S, et al. Ki-1-positive anaplastic large-cell lymphoma with mediastinal involvement. Nihon Kyobu Shikkan Gakkai Zasshi. 1997;35:660–664.
Kayao J, Tamaru J, Wakita H, et al. Anaplastic large cell lymphoma of the mediastinum diagnosed by transbronchial scratch cytology. A case report. Acta Cytol. 2002;46:405–411.
Quesada AE, Medeiros LJ, Clemens MW, et al. Breast implant-associated anaplastic large cell lymphoma: a review. Mod Pathol. 2019;32:166–188.
Foss HD, Anagnostopoulos I, Araujo I, et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood. 1996;88:4005–4011.
Shen J, Medeiros LJ, Li S, et al. CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma. Hum Pathol. 2020;98:1–9.
Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124:1473–1480.
Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9:822–830.
Lin O, Frizzera G. Angiomyoid and follicular dendritic cell proliferative lesions in Castleman’s disease of hyaline-vascular type: a study of 10 cases. Am J Surg Pathol. 1997;21:1295–1306.
Ohgami RS, Zhao S, Ohgami JK, et al. TdT+ T-lymphoblastic populations are increased in Castleman disease, in Castleman disease in association with follicular dendritic cell tumors, and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2012;36:1619–1628.
Ohgami RS, Arber DA, Zehnder JL, et al. Indolent T-lymphoblastic proliferation (iT-LBP): a review of clinical and pathologic features and distinction from malignant T-lymphoblastic lymphoma. Adv Anat Pathol. 2013;20:137–140.
Kansal R, Nathwani BN, Yiakoumis X, et al. Exuberant cortical thymocyte proliferation mimicking T-lymphoblastic lymphoma within recurrent large inguinal lymph node masses of localized Castleman disease. Hum Pathol. 2015;46:1057–1061.
Nathwani BN, Kansal R, Yiakoumis X, et al. Indolent T-lymphoblastic proliferation: a name with specific meaning—reply. Hum Pathol. 2015;46:1786–1787.
Sun X, Chang KC, Abruzzo LV, et al. Epidermal growth factor receptor expression in follicular dendritic cells: a shared feature of follicular dendritic cell sarcoma and Castleman’s disease. Hum Pathol. 2003;34:835–840.